Detection of COX-2 in liquid biopsy of patients with prostate cancer

• Published in: Journal of clinical pathology Vol. 76; no. 3; p. 189
• Main Authors: Pereira, Vanessa Silva, Alves, Beatriz da Costa Aguiar, Waisberg, Jaques, Fonseca, Fernando, Gehrke, Flavia
• Format: Journal Article
• Language: English
• Published: England 01-03-2023
• Subjects: Aged; Biopsy; Cyclooxygenase 2 - genetics; Humans; Liquid Biopsy; Male; Neoplasm Grading; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - genetics; RNA; prostaglandins; prostate; blood proteins; biomarkers; tumour
• ISSN: 1472-4146
• DOI: 10.1136/jclinpath-2021-207755

To determine the profile of
gene expression in patients with prostate cancer attended at the ABC University Health Center outpatient clinic and correlate the results with patients' anatomopathological examinations. Prostate cancer is the sixth most common type of cancer worldwide and the second in Brazil.
expression is associated with an unfavourable prognosis.
15.0 mL of peripheral blood were collected from 24 patients and 25 healthy men. RNA extraction was performed using the QIAamp RNA Blood Mini Kit. Complementary DNA synthesis was performed using SuperScript II RNAse Reverse Transcriptase. Quantitative real-time PCR was performed with specific
oligonucleotides and the endogenous
gene.
The mean age of the patients was 69 years old. The Gleason scoring system showed 37.5% of patients with Gleason 6 (slow growth, low risk), 45.8% with Gleason 7 (intermediate risk) and 16.7% with Gleason 8 or 9 (risk of high-grade cancer). The median
expression in the study group was 0.97, while in the control group it was 0.11 (p<0.045).
Patients with prostate cancer showed higher
expression at diagnosis compared with the control group. Since
detection associated with prostate-specific antigen dosage shows promise as a biomarker for diagnosis and prognosis in patients with prostate cancer, further research is required to confirm these findings.